Poll|Articles|April 18, 2024

Are You Attending the 2024 APA Annual Meeting?

Let us know if we'll see you there!

We'll be on the ground live at the 2024 American Psychiatric Association Annual Meeting in New York. Will we see you there?

Are you attending the 2024 APA Annual Meeting live in New York?

What's your favorite kind of conference coverage content?

If you cannot attend, you can keep up with all our latest coverage here at psychiatrictimes.com!

Newsletter

Receive trusted psychiatric news, expert analysis, and clinical insights — subscribe today to support your practice and your patients.

Subscribe

Related Content

What Does Interventional Psychiatry Actually Mean? Reframing Non-Standard Treatments for Depression

ByLara Shirikjian, MD

July 31st 2026

Gus Alva, MD, on Agitation, Psychosis, and Cognition in Alzheimer Disease

ByGustavo Alva, MD, DFAPA

July 31st 2026

Real-World and Long-Term Trial Data Show Xanomeline/Trospium Cuts Hospitalizations, Antipsychotic Burden in Schizophrenia

ByPsychiatric Times Editors

July 30th 2026

What's New in Psychiatric Treatment? Highlights From the 2026 Southern California Psychiatry Conference

ByJessica Walters

July 30th 2026

Making Sense of the New Alzheimer Treatment Landscape, With Aaron Ritter, MD

ByJessica Walters,Aaron Ritter, MD

July 30th 2026

Latest CME

Video

(CME Track) SoCal Psych 2025: Overcoming Barriers to Long-Acting Injectable Agents in Schizophrenia

Gus Alva, MD, DFAPA; Ilan Melnick, MD

Video

Live Expert Illustrations & Commentary™: Visualizing Novel Therapeutic Targets for Patients with Major Depressive Disorder

Jason Kellogg, MD; Gus Alva, MD, DFAPA; Melanie Barrett, MD; Yvette Elpidio, MSN, FNP-C

In-Person Event

Jersey City Psychiatry

October 2-3, 2026

Register now!

Video

Clear Skin, Clear Mind: Integrating Mental Health into Psoriasis Care

John Koo, MD; T.J. Chao, MPAS, PA-C

Video

(CPE Track) SoCal Psych 2025: Overcoming Barriers to Long-Acting Injectable Agents in Schizophrenia

Gus Alva, MD, DFAPA; Ilan Melnick, MD

Video

Live Expert Illustrations & Commentary™: Visualizing Novel Therapeutic Targets for Patients with Major Depressive Disorder

Jason Kellogg, MD; Gus Alva, MD, DFAPA; Melanie Barrett, MD; Yvette Elpidio, MSN, FNP-C

Are You Attending the 2024 APA Annual Meeting?

Related Content

What Does Interventional Psychiatry Actually Mean? Reframing Non-Standard Treatments for Depression

Gus Alva, MD, on Agitation, Psychosis, and Cognition in Alzheimer Disease

Real-World and Long-Term Trial Data Show Xanomeline/Trospium Cuts Hospitalizations, Antipsychotic Burden in Schizophrenia

What's New in Psychiatric Treatment? Highlights From the 2026 Southern California Psychiatry Conference

Making Sense of the New Alzheimer Treatment Landscape, With Aaron Ritter, MD

Latest CME

(CME Track) SoCal Psych 2025: Overcoming Barriers to Long-Acting Injectable Agents in Schizophrenia

Live Expert Illustrations & Commentary™: Visualizing Novel Therapeutic Targets for Patients with Major Depressive Disorder

Jersey City Psychiatry

Clear Skin, Clear Mind: Integrating Mental Health into Psoriasis Care

(CPE Track) SoCal Psych 2025: Overcoming Barriers to Long-Acting Injectable Agents in Schizophrenia

Live Expert Illustrations & Commentary™: Visualizing Novel Therapeutic Targets for Patients with Major Depressive Disorder

Trending on Psychiatric Times

Interdisciplinary Consensus Guidelines on Stuttering (Childhood-Onset Fluency Disorder): Addressing Issues in Diagnosis, Treatment, and Unmet Needs

DT120 (Lysergide) Shows Rapid, Lasting Relief for Generalized Anxiety in Phase 3 Trial

TRD: Matching Patients to the Right Treatment

Brain Trust: Carl Salzman, MD, on Benzodiazepine Mindful Prescribing, Misuse, and Dependence

New in Narcolepsy: Pharmacology Updates